validation of a french version of FACT-GOG/NTX and using this questionnaire to evaluate the incidence of the peripheral neurotoxicity in patients treated for ovarian cancer with paclitaxel associated or not with EPO.

Inclusion Criteria:

• Femal patient aged > 18 years
• Histologically proven diagnosis of cancer of the ovary, the fallopian tube or peritoneal
• patients whose disease progresses or relapses
• patients having received at least a line of platinum-based chemotherapy
• patients whose treatment of relapse is envisaged to comprise paclitaxel
• patients who will receive EPO for treatment of their anaemia
• ECOG performans status < 2
• life expectancy > 16 weeks
• patient who has clearly given her consent by signing on informed consent form prior to participation

Exclusion Criteria:

• peripheral neuropathy grade > 2
• history of ischemic cardiopathy, congestive heart failure (NYHA>2), arrhythmia, hypertension or significant valvulopathy
• abnormal biological values
• A therapy or a serious disease which could involve a risk for the patient or interfere with the aims of the study
• patient who is pregnant, breast feeding or using inadequate contraception
• concomitant therapy by a potentially neurotoxic drug
• concomitant inclusion in another therapeutic trial which could interfere with the aims of the study
• patient who for familial, sociological, geographical or psychological condition could not be followed correctly